Previous clinical studies have documented marked elevations of circulating galectin-3 concentrations in patients with HF and showed that these levels can predict mortality and adverse outcomes, which suggests a role for galectin-3 as a surrogate biomarker for prognosis (32, 33). This evidence concerns the gene LGALS3 and hydrops fetalis.